Interim Analyses in Clinical Trials

By  

Heart Drug, Vol. 3, Iss. 2, 2003-08 ,pp. : 113-116

Karger

Access to resources Recommend Favorite

Optimal Timing for Interim Analyses in Clinical Trials

By Togo Kanae   Iwasaki Manabu  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 1067-1080

Taylor & Francis Ltd

Access to resources Recommend Favorite

Strategies to Measure and Improve Patient Adherence in Clinical Trials

By Matsui Doreen  

Pharmaceutical Medicine, Vol. 23, Iss. 5-6, 2009-10 ,pp. : 289-297

Adis International

Access to resources Recommend Favorite

A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET)

By Cleland John   Goode Kevin   Erhardt Leif   Remme Willem   Charlesworth Andrew   Poole-Wilson Philip   Di Lenarda Andrea   Hanrath Peter   Komajda Michel   Metra Marco   Swedberg Karl   Torp-Pedersen Christian  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 2, 2004-03 ,pp. : 139-152

Springer Publishing Company

Access to resources Recommend Favorite

Ethical Issues in Including Pediatric Cancer Patients in Drug Development Trials

By Aleksa K.  

Pediatric Drugs, Vol. 4, Iss. 4, 2002-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite